Stock Track | NovoCure Soars 26.67% in Pre-market on FDA Approval for Pancreatic Cancer Treatment

Stock Track

02/12

NovoCure's stock surged 26.67% in pre-market trading following the U.S. Food and Drug Administration's approval of its Optune Pax® device for the treatment of locally advanced pancreatic cancer.

The FDA approval, announced by the company, marks the first new treatment for this condition in nearly 30 years. Optune Pax is a wearable device that delivers Tumor Treating Fields (TTFields) noninvasively and is approved for use in combination with gemcitabine and nab-paclitaxel chemotherapy.

The regulatory decision is based on positive results from the Phase 3 PANOVA-3 clinical trial, which demonstrated a statistically significant improvement in median overall survival for patients treated with Optune Pax and chemotherapy compared to chemotherapy alone. The trial met its primary endpoint, showing a median overall survival of 16.2 months versus 14.2 months for the control group.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1158168445"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1158168445\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1158168445?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 17:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158168445","market":"nz","top_or_hot":-1,"title":"Stock Track | NovoCure Soars 26.67% in Pre-market on FDA Approval for Pancreatic Cancer Treatment","media":"Stock Track","content":"<p>NovoCure's stock surged 26.67% in pre-market trading following the U.S. Food and Drug Administration's approval of its Optune Pax® device for the treatment of locally advanced pancreatic cancer.</p><p>The FDA approval, announced by the company, marks the first new treatment for this condition in nearly 30 years. Optune Pax is a wearable device that delivers Tumor Treating Fields (TTFields) noninvasively and is approved for use in combination with gemcitabine and nab-paclitaxel chemotherapy.</p><p>The regulatory decision is based on positive results from the Phase 3 PANOVA-3 clinical trial, which demonstrated a statistically significant improvement in median overall survival for patients treated with Optune Pax and chemotherapy compared to chemotherapy alone. The trial met its primary endpoint, showing a median overall survival of 16.2 months versus 14.2 months for the control group.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | NovoCure Soars 26.67% in Pre-market on FDA Approval for Pancreatic Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | NovoCure Soars 26.67% in Pre-market on FDA Approval for Pancreatic Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-12 17:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NovoCure's stock surged 26.67% in pre-market trading following the U.S. Food and Drug Administration's approval of its Optune Pax® device for the treatment of locally advanced pancreatic cancer.</p><p>The FDA approval, announced by the company, marks the first new treatment for this condition in nearly 30 years. Optune Pax is a wearable device that delivers Tumor Treating Fields (TTFields) noninvasively and is approved for use in combination with gemcitabine and nab-paclitaxel chemotherapy.</p><p>The regulatory decision is based on positive results from the Phase 3 PANOVA-3 clinical trial, which demonstrated a statistically significant improvement in median overall survival for patients treated with Optune Pax and chemotherapy compared to chemotherapy alone. The trial met its primary endpoint, showing a median overall survival of 16.2 months versus 14.2 months for the control group.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVCR","symbol_name":"NovoCure Limited","start_time":0,"source_url":"","article_id":"1158168445","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158168445","pubTimestamp":1770889594,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"NovoCure's stock surged 26.67% in pre-market trading following the U.S. Food and Drug Administration's approval of its Optune Pax® device for the treatment of locally advanced pancreatic cancer.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVCR":"NovoCure Limited"},"translate_title":"个股追踪|NovoCure上市前暴涨26.67%获FDA批准治疗胰腺癌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCR":1},"content_text":"NovoCure's stock surged 26.67% in pre-market trading following the U.S. Food and Drug Administration's approval of its Optune Pax® device for the treatment of locally advanced pancreatic cancer.The FDA approval, announced by the company, marks the first new treatment for this condition in nearly 30 years. Optune Pax is a wearable device that delivers Tumor Treating Fields (TTFields) noninvasively and is approved for use in combination with gemcitabine and nab-paclitaxel chemotherapy.The regulatory decision is based on positive results from the Phase 3 PANOVA-3 clinical trial, which demonstrated a statistically significant improvement in median overall survival for patients treated with Optune Pax and chemotherapy compared to chemotherapy alone. The trial met its primary endpoint, showing a median overall survival of 16.2 months versus 14.2 months for the control group.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}